Heparin Treatment in Cerebral Sinus and Venous Thrombosis: Patients at Risk of Fatal OutcomeMehraein S.a · Schmidtke K.b · Villringer A.a · Valdueza J.M.a · Masuhr F.a
aDepartment of Neurology, Charité, Humboldt University, Berlin, and bCentre for Geriatric Medicine and Gerontology, University of Freiburg, Freiburg, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
We performed a retrospective analysis of 79 patients with cerebral sinus venous thrombosis, who were treated with a fixed regimen of dose-adjusted intravenous heparin, to determine predictors of a fatal course. The parameters investigated were the state of consciousness and the presence of intracranial haemorrhage (ICH) at the start of heparin treatment, involvement of the internal venous system, mean delay from initial symptom to stupor or coma and from initial symptom to hospital admission, focal neurological deficits, mean intracranial circulation time (ICT) on conventional angiography, and age and sex distribution. Mortality rate was 10% in this series (8/79). There was a strong link between the outcome and the level of vigilance: 53% of the patients with stupor or coma at the start of the heparin therapy died (8/15), whereas all of the 64 patients with no more than mildly impaired vigilance survived (p < 0.00001). Furthermore, mean age and mean ICT were significantly higher in the group of patients who died. There was a statistical trend (p = 0.056) for ICH to be more frequent in cases with fatal outcome, but there was reason to assume that ICH represented an epiphenomenon of a severe course rather than an independent predictor. Other investigated parameters were not linked with a fatal outcome.
© 2003 S. Karger AG, Basel
- Bousser MG: Cerebral venous thrombosis. Nothing, heparin, or local thrombolysis? Stroke 1999;30:481–483.
- Einhäupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P: Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597–600.
- de Bruijn SFTM, Stam J: Randomized placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30:484–488.
- Barnwell SL, Higashida RT, Halbach VV, Dowd CF, Hieshima GB: Direct endovascular thrombolytic therapy for dural sinus thrombosis. Neurosurgery 1991;28:135–142.
- Eskridge JM, Wessbecher FW: Thrombolysis for superior sagittal sinus thrombosis. J Vasc Interv Radiol 1991;2:89–93.
- Griesemer DA, Theodorou AA, Berg R, Spera TD: Local fibrinolysis in cerebral venous thrombosis. Pediatr Neurol 1994;10:78–80.
Higashida RT, Helmer E, Halbach VV, Hieshima GB: Direct thrombolytic therapy for superior sagittal sinus thrombosis. AJNR Am J Neuroradiol 1989;10:4–6.
- Horowitz M, Purdy P, Unwin H, Carstens G 3rd, Greenlee R, Hise J, Kopitnik T, Batjer H, Rollins N, Samson D: Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995;38:58–67.
- Smith TP, Higashida RT, Barnwell SL, Halbach VV, Dowd CF, Fraser KW, Teitelbaum GP, Hieshima GB: Treatment of dural sinus thrombosis by urokinase infusion. AJNR Am J Neuroradiol 1994;15:801–807.
- Tsai FY, Higashida RT, Matovich V, Alfieri K: Acute thrombosis of the intracranial dural sinus: Direct thrombolytic treatment. AJNR Am J Neuroradiol 1992;13:1137–1141.
- Frey JL, Muro GJ, McDougall CG, Dean BL, Jahnke HK: Cerebral venous thrombosis: Combined intrathrombus rtPA and intravenous heparin. Stroke 1999;30:489–494.
- Kim SY, Suh JH: Direct endovascular thrombolytic therapy for dural sinus thrombosis: Infusion of alteplase. Am J Neuroradiol 1997;18:639–645.
- Villringer A, Rosen BR, Belliveau JW, Ackermann JL, Lauffer RB, Buxton RB, Chao YS, Wedeen VJ, Brady TJ: Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects. Magn Reson Med 1988;6:164–174.
- Haase A, Matthaei D, Hanicke W, Frahm J: Dynamic digital subtraction imaging using fast low-angle shot MR movie sequence. Radiology 1986;160:537–541.
- Bousser MG, Chiras J, Bories JB, Castaigne P: Cerebral venous thrombosis – a review of 38 cases. Stroke 1985;16:199–210.
Krayenbühl H: Cerebral venous and sinus thrombosis. Clin Neurosurg 1967;14:1–24.
Barinagarrementeria F, Cantu C, Arredondo H: Aseptical cerebral venous thrombosis: Proposed prognostic scale. J Stroke Cerebrovasc Dis 1992;2:34–39.
- Bots GT: Thrombosis in the galenic system veins in adults. Acta Neuropathol (Berl) 1971;17:227–233.
- Crawford SC, Digre KB, Palmer CA, Bell DA, Osborne AG: Thrombosis of the deep venous drainage in the brain of adults. Analysis of seven cases with review of the literature. Arch Neurol 1995;52:1101–1108.
- Milandre L, Pellissier JF, Vincentelli F, Khalil R: Deep cerebral venous system thrombosis in adults. Eur Neurol 1990;30:93–97.
- de Bruijn SFTM, Stam J, for the Cerebral Venous Sinus Study Group: Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. J Neurol Neurosurg Psychiatry 2001;70:105–108.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.